Please ensure Javascript is enabled for purposes of website accessibility

Why Bausch Health Companies Stock Zoomed 8% Higher Today

By Eric Volkman – Sep 21, 2021 at 4:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One analyst crunches the numbers to come up with a share price valuation well above current levels.

What happened

Bausch Health Companies (BHC 2.99%) was a very healthy stock Wednesday. A bullish note from an analyst at an influential bank put some real zip in the shares, and they closed the day more than 8% higher.

So what

Analyst Chris Schott from JPMorgan Chase's J.P. Morgan pointed out in his note that a sum-of-the-parts calculation indicates to him that Bausch stock could be worth around $40 (although he's maintaining his $38 price target). That $40 is more than 50% above Monday's $26.10 closing price.

The prognosticator is also maintaining his overweight (buy) recommendation on the stock.

Stethescope atop US currency and insurance claim form.

Image source: Getty Images.

Much of Schott's estimate consists of the Bausch & Lomb eye care division, which he is assuming contributes $30 to that total. He values the Solta dermatology-device unit at $7 per share, with the company's pharmaceutical operations making up the remainder.

As such, Bausch presents in his view an "attractive valuation argument" at a "fairly near-term time horizon over which this value could be realized." In other words, it's a buy on share price weakness that could see plenty of upside before long.

Now what

Bausch hasn't been a popular stock lately. Many investors clearly don't feel a looming split of the company into two component parts will improve either business.

Meanwhile, Bausch's recent quarterly earnings reports have been disappointing, with a revenue-guidance chop in the most recent one, and a top-line miss in its predecessor. It remains to be seen whether Schott's new note will continue to bring the bulls back to the stock.

JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies. The Motley Fool has a disclosure policy.

Stocks Mentioned

Bausch Health Companies Stock Quote
Bausch Health Companies
$7.93 (2.99%) $0.23
JPMorgan Chase & Stock Quote
JPMorgan Chase &
$135.16 (-0.79%) $-1.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.